Department of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, No. 34 North Zhongshan Road, Quanzhou, 362000, Fujian, China.
Department of Neurosurgery, Hui'an County Hospital of Fujian Province, Quanzhou, Fujian, China.
Stem Cell Res Ther. 2022 Jun 28;13(1):281. doi: 10.1186/s13287-022-02965-2.
Non-traumatic intracerebral hemorrhage is a highly destructive intracranial disease with high mortality and morbidity rates. The main risk factors for cerebral hemorrhage include hypertension, amyloidosis, vasculitis, drug abuse, coagulation dysfunction, and genetic factors. Clinically, surviving patients with intracerebral hemorrhage exhibit different degrees of neurological deficits after discharge. In recent years, with the development of regenerative medicine, an increasing number of researchers have begun to pay attention to stem cell and exosome therapy as a new method for the treatment of intracerebral hemorrhage, owing to their intrinsic potential in neuroprotection and neurorestoration. Many animal studies have shown that stem cells can directly or indirectly participate in the treatment of intracerebral hemorrhage through regeneration, differentiation, or secretion. However, considering the uncertainty of its safety and efficacy, clinical studies are still lacking. This article reviews the treatment of intracerebral hemorrhage using stem cells and exosomes from both preclinical and clinical studies and summarizes the possible mechanisms of stem cell therapy. This review aims to provide a reference for future research and new strategies for clinical treatment.
非创伤性脑出血是一种具有高死亡率和高发病率的高度破坏性颅内疾病。脑出血的主要危险因素包括高血压、淀粉样变性、血管炎、药物滥用、凝血功能障碍和遗传因素。临床上,脑出血后出院的存活患者表现出不同程度的神经功能缺损。近年来,随着再生医学的发展,越来越多的研究人员开始关注干细胞和外泌体治疗作为脑出血治疗的新方法,因为它们在神经保护和神经修复方面具有内在的潜力。许多动物研究表明,干细胞可以通过再生、分化或分泌直接或间接地参与脑出血的治疗。然而,由于其安全性和疗效的不确定性,临床研究仍然缺乏。本文综述了从临床前和临床研究中使用干细胞和外泌体治疗脑出血的情况,并总结了干细胞治疗的可能机制。本文旨在为未来的研究和临床治疗的新策略提供参考。